I am encouraged that Botanix said that 50% of dermatologists they spoke with would try Sofdra as first line, and they plan on having a big sales force visiting those 4500 dermatologists.
Their sales and market penetration plan, looks very aggressive, and I don't know if Kaken have taken steps anything like what BOT are proposing.
Of interest, 85% of patients for the BOT trial said they felt an improvement, whereas only around 65% from qbrexa trial ( current best approved treatment ) said they felt improvement. The gravametric sweat reduction was similar at close to 70% for the two products. Price is 600 to 700 per month for qbrexa.
So while not 100%, according to the patients, 85% vs 65%, its a better product than the only FDA approved treatment currently available , and will be at a similar price.
- Forums
- ASX - By Stock
- BOT
- Where will we be in 12 months time?
Where will we be in 12 months time?, page-195
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.5¢ |
Change
-0.010(2.41%) |
Mkt cap ! $734.6M |
Open | High | Low | Value | Volume |
42.0¢ | 42.5¢ | 39.5¢ | $3.680M | 8.989M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 297011 | 40.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 12027 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 292011 | 0.400 |
15 | 448461 | 0.395 |
6 | 156017 | 0.390 |
9 | 94706 | 0.385 |
15 | 342471 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 12027 | 3 |
0.410 | 278359 | 4 |
0.415 | 245758 | 5 |
0.420 | 204502 | 9 |
0.425 | 336469 | 7 |
Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |